Search results
A new COVID variant is dominant in the US: What are its symptoms?
TODAY via Yahoo News· 4 days agoThe new "FLiRT" COVID-19 variants, including KP.3 and KP.2, are spreading in the United States. Will...
Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including...
FOX 23 News Albany· 16 hours agoIn the results, olverembatinib showed excellent durable clinical benefits and favorable long-term tolerability in patients who...
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
NewMediaWire via Yahoo Finance· 1 hour agoThree of the world's leading key opinion leaders (KOL) in neuroscience and schizophrenia to review...
Titanic sub disaster one year on: How the world watched a tragedy unfold over four days
The Independent via Yahoo News· 12 hours ago“At this time, we do not have a projected completion date. The latter part of the fact-finding phase...
Chinese journalist who promoted #MeToo movement sentenced to 5 years in prison
Dayton Daily News· 4 days agoThe verdict provided to The Associated Press stated that Huang Xueqin would also face a fine of 100,000 yuan ($14,000), underscoring the ruling Communist Party’s intolerance of any activism ...
The ozone layer is recovering faster than expected, thanks to global cooperation
Salon via Yahoo News· 5 days agoBut to get there will require cooperation... and Global Cooling Pledge should ensure that, in time,...
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
Morningstar· 1 day ago(Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction...adding ...
Consumer Subscription Stocks Q1 Earnings: Roku (NASDAQ:ROKU) Firing on All Cylinders
StockStory via Yahoo Finance· 5 days agoEarnings results often indicate what direction a company will take in the months ahead. With Q1 now...
Affimed N.V. (NASDAQ:AFMD) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoReported EPS is $-1.38, expectations were $-1.73. Operator: Good day, everyone and welcome to...
Arthrosi Presents Positive Phase 2 Data for AR882 at the European Alliance of Associations for...
Tehachapi News· 4 days agoArthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels ...